Search

Factor IX Complex (Human)

For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin.

Dabigatran etexilate

[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]

Bezisterim

L-Glutamine

An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.

Yellow fever vaccine

10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days [FDA … It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118

Unoprostone

Unoprostone isopropyl is a prostaglandin analogue. Ophthalmic Solution 0.15% is a synthetic docosanoid. Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate....

Guaifenesin

After the negotiation between FDA and major manufacturers, a voluntary transition of labels for not using guaifenesin in children under the age of 4 years was endorsed by FDA in 2008 [F4525]. … Regardless, on March 1, 2007, the FDA received a petition asking the FDA to notify the public that some antitussives, expectorants, decongestants, antihistamines, and cough/cold combinations are not known

Cupric oxide

Cupric oxide, or copper (II) oxide, is an inorganic compound with the chemical formula CuO. Cupric oxide is used as a precursor in many copper-containing products such as wood preservatives and ceramics. Cupric oxide may be found in over...

Hydroxychloroquine

[L14312]** Hydroxychloroquine was granted FDA approval on 18 April 1955.[L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546] … [A192132] **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.